Sign up


Match Document Document Title
8846686 Compounds useful as inhibitors of ATR kinase  
The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this...
8846623 Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis  
Cancer-targeting peptides having a PX1LX2 motif, in which X1 is His or an amino acid residue with a hydrophobic side chain and X2 is Pro, Phe, or Trp. Also disclosed herein are conjugates...
8846771 Compositions and methods of delivery of pharmacological agents  
The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human...
8841256 P2X7: inhibition of epithelial cancers and papillomas  
The present invention demonstrates that P2X7 receptor induced apoptosis may be specific for cancerous cells. Treatment with the P2X7 ligand BzATP, increased cellular apoptosis with no associated...
8841414 Targeted delivery of therapeutic peptides by thermally responsive biopolymers  
A compound including a cell penetrating peptide (CPP), an elastin-like polypeptide (ELP), and a therapeutic peptide (TP) can be preferentially directed to a target site by applying hyperthermia....
8840878 Peptidomimetic sulfamide compounds and antiviral uses thereof  
The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
8841251 Method for making a homogenous vaccine composition comprising a conjugate of EGF and 64K for the treatment of tumors  
A vaccine composition for therapeutic use thereof on cancer patients includes a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and a combining protein P64k for performing a...
8840886 Method of treating cancer with DLL4 antagonist and chemotherapeutic agent  
The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that...
8841257 Inhibitors of STAT3 and uses thereof  
Compounds which inhibit the activity of signal transducer and activator of transcription 3 (STAT3) are provided together with methods of making and using the same. The compounds are designed to...
8840874 Vascular delivery systems  
The site-specific expression of selectins on endothelial cells of blood vessels during angiogenesis provides an opportunity to target anti-cancer drugs to the vascular endothelium to extend the...
8840902 Tumor vaccination involving a humoral immune response against self-proteins  
The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an...
8835394 Treatment for basal cell carcinoma  
The present invention provides a method of treating basal cell carcinoma in a subject. Generally, the method includes administering to the subject an amount of IRM compound effective for treating...
8834876 Therapeutic agent for hematopoietic tumors  
An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon α, interferon γ, or the IRF-2 protein as an active ingredient, as w...
8828417 Bioactive coating for an implantable device or bioprosthesis  
For an implantable device intended for use in the human body an in-vivo colonization with autologous cells is often desired. The devices, especially prosthetic devices like implant tissues, grafts,...
8828391 Method for EGFR directed combination treatment of non-small cell lung cancer  
The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine...
8828381 Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas  
A method for enhancing the therapeutic effect of cytokine treatment is disclosed. More specifically the present invention relates to a method for administering to a tumor patient a therapeutic dose...
8828685 Monomeric forms of human aminoacyl-t-RNA synthetases having non-canonical biological activities  
Isolated monomelic aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
8828944 Compounds and uses thereof to induce an immunogenic cancer cell death in a subject  
The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility...
8828957 Methods for generating immunity to antigen  
Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vectors comprises a...
8822442 Somatostatin-dopamine chimeric analogs  
The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.
8821883 Method of treating B cell cancers by administering truncated BAFF receptors  
The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also...
8822421 E2F as a target of hormone refractory prostate cancer  
The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also...
8821872 Identification and characterization of a specific CCK-C receptor antibody for human pancreatic cancer and its use for early detection and staging of pancreatic cancer  
Human pancreatic cancer cells possess a distinct plasma membrane CCK receptor variant that can be differentiated from the classic CCK-B receptor with selective monoclonal antibodies. Use of this...
8822419 Membrane resident peptide in anti-cancer peptides causes tumor cell necrosis rather than apoptosis of cancer cells  
An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and...
8822420 Peptides and aptamers thereof as specific modulators of mutant p53 function  
In the present application isolated peptides and aptamers thereof able to interact with structural and conformational p53 mutants within the region of the wild-type p53 DNA binding core domain...
8822422 Antitumor agent  
An antitumor agent containing, in combination, at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor...
8821867 4-1BB binding molecules  
The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic...
8815804 Methods and compositions related to targeting tumors and wounds  
Disclosed are compositions and methods useful for targeting tumors, sites of injury and blood clots. The compositions and methods are based on peptide sequences that selectively bind to and home to...
8815805 Formulations having an antagonist of α5β1 for anti-angiogenesis and cancer treatment  
The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an α5β1 antagonist with an α...
8809280 Therapeutic peptides  
The present invention provides a peptide, peptidomimetic or amino acid derivative having a net positive charge of at least +2 and incorporating a disubstituted β amino acid, each of the ...
8808698 Methods for inhibition of lymphangiogenesis and tumor metastasis  
The present invention is directed to compositions and methods for inhibiting the development of new lymphatic vessels, and for inhibiting tumor cell dissemination through the lymphatics. In...
8802627 Fusion protein composed of matrix metalloproteinase-2 inhibitor peptide derived from amyloid-B precursor protein and tissue inhibitor of metalloproteinase-2  
The present invention provides an agent capable of inhibiting MMP-2 specifically. Disclosed is a fusion molecule composed of a β-amyloid precursor protein molecule-derived domain having an ...
8802153 System for targeted delivery of therapeutic agents  
The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides...
8802635 Antioxidant, anti-inflammatory, anti-radiation, metal chelating compounds and uses thereof  
Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such...
8802632 Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof  
Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a...
8802631 Peptides and methods for the treatment of gliomas and other cancers  
The invention is based on the discovery that STM/Hop promotes proliferation of human glioblastoma-derived cells but not of normal astrocytes and that the proliferation requires the binding of...
8802634 CD40-L Inhibitory Peptides  
The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signalling that are not derived from a natural binding partner of CD40L such as CD40, or from a native...
8802618 Controlled modulation of amino acid side chain length of peptide antigens  
The invention provides a method for the creation of peptide antigens comprising epitopes with at least a first modification comprising a shortened or lengthened amino acid side chain. By extension...
8796220 Vaccine for the prevention of the recurrence HER2/neu expressing cancer  
The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective...
8796219 Target-activated cell/tissue-penetrating peptide for delivery of impermeable compounds and use thereof  
The present invention relates to a target-activated cell/tissue-penetrating peptide for delivery of impermeable compounds (Target Activated Cell/tissue Translocation peptide for Impermeable...
8795627 Treatment of liver disorders by administration of RAP conjugates  
The present invention relates to the use of receptor-associate protein (RAP) and fragments and variants thereof to improve delivery of therapeutic compounds to the liver and provides methods to...
8796218 Complex and production process  
A method for preparing a biologically active complex, said method comprising a recombinant protein having the sequence of α-lactalbumin, such as human α-lactalbumin or a fragment thereof but w...
8791073 Peptide-modified polyurethane compositions and associated methods  
Peptide-modified polyurethanes comprising the reaction product of an isocyanate, a chain extender, and a peptide are provided. Also provided processes for making a peptide-modified polyurethane...
8791076 Agonists of neurotrophin receptors and their use as medicaments  
The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are...
8791075 Methods and compositions for inhibition of BCL6 repression  
The invention is directed to a compound that binds to a BCL6 lateral groove and prevents binding of a corepressor to the lateral groove. The present invention is further directed to methods for...
8791074 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors  
The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by...
8784811 Method of treating cancer using antibodies to a non-ligand binding region of NOTCH1  
The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis,...
8785392 Method for inhibiting cancer metastasis by administration of the extracellular domain DLK1 or a DLK1-FC fusion protein  
A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E...
8784797 Methods, pharmaceutical compositions and kits for use in the treatment of adult T-cell leukemia/lymphoma  
The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a...
8785371 Drug delivery of temozolomide for systemic based treatment of cancer  
The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a...